Oncosec Medical Incorporated · OTC:ONCSQ
Oncosec Medical — Corporate Update (April 2023)
33 slides from Oncosec Medical's corporate update, Apr 27, 2023
Slide 1: Corporate Update
(©) ONCOSeC IMMUNOTHERAPIES. Corporate Update Non-Confidential Presentation April 2023
Slide 2: Risk Factors and Forward-Looking Statements
Risk Factors and Forward-Looking Statements This presentation contains forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Forward-looking statements provide the Com
Slide 3: Awakening the immune system to eradicate cancer
Awakening the immune system to eradicate cancer TAvo™ Platform Clinical Programs Investment Context @ Proprietary TAVO™ electroporation platform to elicit tumor-directed immune cell activation by stimulating the patient’s immune system without neoantigen delivery Intra-tumoral delivery of interleuki
Slide 4: OncoSec as a future leader of immuno-oncology therapy
OncoSec as a future leader of immuno-oncology therapy Addressing unmet clinical needs by leveraging innovative intratumoral drug delivery Vision + We aspire to awaken the immune system to eradicate cancer and restore patients’ lives. Mission * Provide safe and effective solutions for cancer patients
Slide 5: TAVO-EP platform designed to address key clinical unmet needs
TAVO™-EP platform designed to address key clinical unmet needs Plasmid Electrode Gene Injection Insertion Delivery Total Process: ~30 Minutes ———> Unique intratumoral delivery applicable to cutaneous, subcutaneous, and nodal lesions Demonstrated clinical activity for patients who have progressed on
Slide 6: TAVO-EP plus KEYTRUDA - rationale for neoadjuvant melanoma
TAVO™-EP plus KEYTRUDA® - rationale for neoadjuvant melanoma Going beyond immune checkpoint inhibitors and cancer vaccines, neoadjuvant melanoma represents promising option for patients with advanced melanoma? * TAVO™-EP in the neoadjuvant setting offers a novel “personalized off-the-shelf therapeut
Slide 7: The IO market driven by checkpoint inhibitors is growing rapidly
The IO market driven by checkpoint inhibitors is growing rapidly Global Market Analysis and Forecast of Immuno-Oncology (10) Approaches * Immuno-oncology (IO) approaches have 160 $143 B demonstrated significant, durable response 140 rates in a broad range of cancer types 120 CCAGR 23% ) 23% 100 8 *
Slide 8: Despite IO success, great unmet need remains in melanoma
Despite IO success, great unmet need remains in melanoma Primary Resistance Secondary Resistance Most patients receive PD-1 mono- or combination therapy in first line, yet 40 — 65% fail to respond? Among initial PD-1 responders, ~40% acquire resistance and progress within 5 years? Key Unmet Needs Po
Slide 9: Cancer vaccines aim to induce cancer immunity to close ICI gap
Cancer vaccines aim to induce cancer immunity to close ICI gap ‘Autologous (neo) antigen peptides Autologous subunits Autologous tumor cells (e.g proteins, exosomes) ++adjuvants = zs ’ ba ~, &-@ / 'e'1 Genetically modified ‘Autologous whole tumor autologous tumor cells lysates v Cancer vaccines indu
Slide 10: Melanoma: Neoadjuvant
‘Melanoma: Neoadjuvant TAVO™-EP IL-12 in situ vaccination to awaken the immune system Patient with Systemic elimination accessible melanoma lesions of distant metastases receives TAVO™-EP treatment > Newly activated immune cells can provide long-term immunologic memory for durable responses in patie
Slide 11: TAVO-EP has substantial clinical activity and safety data
TAVO™-EP has substantial clinical activity and safety data * TAVO™-EP has been studied in clinical trials as mono- and combination therapy * TAVO™-EP was administered in most trials as 3 treatments per cycle in 6-week cycles * TAVO™-EP has been administered to more than 230 melanoma patients and ove
Slide 12: Sharpened focus on melanoma and potential in other tumor types
Sharpened focus on melanoma and potential in other tumor types es TAVO™ + omss-104 Neoadjuvant Resectable Locally/ MOFFITT 3 Nivolumab Phase 2 IST! Regionally Advanced Melanoma 2 os WW sae 2 = 2 TAVO™ + Neoadjuvant Resectable Locally / FA eat TOS) Pembrolizumab Phase 2:RCT Regionally Advanced Melano
Slide 13: Neoadjuvant melanoma therapy is gaining traction...
Neoadjuvant melanoma therapy is gaining traction... Southwest Oncology Group (SWOG) trial $1801 Phase 2, n= 313 * Pembrolizumab monotherapy (200 mg IV, Q3W) = Neoadjuvant (3 doses) and adjuvant (15 doses) vs. - Adjuvant (18 doses) * Primary endpoint EFS: - Landmark analysis at 2 years: 72% vs. 49% [
Slide 14: ..but not all patients benefit from neoadjuvant ICI combinations
..but not all patients benefit from neoadjuvant ICI combinations OpACIN-neo trial (Phase 2, n=89) * Ipilimumab plus nivolumab (various dose regimens) om =» z i + IFN-y signature and tumor mutational burden (TMB) in ig baseline tumors predicted better clinical outcomes. 3° — - Patients with baseline
Slide 15: Neoadjuvant Immunotherapy with Intratumoral TAVO plus EP and Nivolumab
oncosec IMMUNOTHERAPIES. Neoadjuvant Immunotherapy with Intratumoral Tavokinogene Telseplasmid (TAVO) plus Electroporation (EP) in Combination with Intravenous Nivolumab in Patients with Operable Locoregionally Advanced Melanoma | hmad A Tarnini, MD, PhO: ‘Zeynep Eroghu, MD: "Amod A Samaik MD: Vonat
Slide 16: Neoadjuvant melanoma Phase 2 IST design and endpoints
site 2022 Neoadjuvant melanoma Phase 2 IST" design and endpoints Neoadjuvant Phase I Neoadjuvant Operable CYCLE 1 CYCLE2 CYCLE3 Locoregionally Advanced a Stage IIIB-D or Stage IVA Melanoma W W YW (Tx, T1-4, N1b-c, REN 4 wks SOC Adjuvant Nivolumab, 480 mg IV with an accessible lesion for electroporat
Slide 17: Bulky tumors disappear with treatment
SITC 2022 Bulky tumors disappear with treatment Day1 Day 8 Day 28 Day 85 (Cycle 1) (Cycle 1) (Cycle 2 Day 1) ht before surgery) ™ RECIST v1.1 CR Pathologic CR @®oncosec
Slide 18: High pathological major response rate with TAVO-EP + nivolumab
High pathological major response rate with TAVO™-EP + nivolumab Saeco No. of TAVO-EP | No. of Nivo Cycles “alae (Gear ee 1 IV Mita) dip 5 1 PD! pNR 2 ic [CD8*TILIPD-L1/TIS 9 3 cR pCR 3 IV (Mia) [CDB*TILIPD-L1/TIS}o 5 3 cR pCR 4 HB [CD8*TILIPD-L1/TIS}o 8 1 cR pCR 5 1B dip 8 3 cR pCR 6 ile [CD8°TILIPD
Slide 19: TAVO-EP Phase 2 neoadjuvant IST: predictive biomarkers
TAVO™-EP Phase 2 neoadjuvant IST: predictive biomarkers Baseline biomarkers predicting no or limited responses to anti-PD-1 mAb in majority of patients + Tumor infiltrating lymphocytes (TIL) are essential for anti-tumor immune responses by producing cytokines . 11s PDL that promote anti-tumor immuni
Slide 20: Inflammatory biomarker changes as early signs of clinical activity
Inflammatory biomarker changes as early signs of clinical activity Peritumoral CD8* cD8* TIL 400: = t00- (non-responder) Predictive biomarker signals change with treatment Enrolled patients (n=15); evaluable baseline and on-treatment tissue (n=5): 1L-12 + 5/5 peritumoral CD8* T cells 7 + 4/5 CD8* TI
Slide 21: Summary of TAVO-EP Phase 2 IST in neoadjuvant melanoma
Summary of TAVO™-EP Phase 2 IST” in neoadjuvant melanoma * Intratumoral TAVO™-EP in combination with nivolumab in neoadjuvant melanoma exhibits encouraging clinical activity and a favorable safety profile * Pathologic complete response (pCR) rate 66.7% and pathologic major response (pMR) rate 88.9%
Slide 22: TAVO-EP melanoma neoadjuvant summary
TAVO™-EP melanoma neoadjuvant summary Challenges Opportunities + ICI followed by surgery is not approved but may become SOC Currently no approved therapies + Ipi/nivo has ~50% pathological complete response rate (pCR), Patients start with accessible disease but high toxicity, including chronic immun
Slide 23: Melanoma: Neoadjuvant
‘Melanoma: Neoadjuvant OncoSec neoadjuvant melanoma Phase 2 randomized trial design N= 3-15 patients Runn Sta Select Arm A dosing regimen N= 84 patients Ss " Stratification: Stage IIIB vs. IIIC vs. IlID electroporation Enroll (Run-In) or Randomize 1:1 to Arm Aor Arm 8 AmB Pembrolizumab + TAVO™-EP Ne
Slide 24: Melanoma: Neoadjuvant
‘Melanoma: Neoadjuvant Run-In Design to assess TAVO™-EP dosing regimen for Ph2 RCT PLANNING & FDA MEETING RUN-IN STAGE oo 12023 ———+— 4-10 months to interim data read-out. ——————— Ad Board meetings April 2023 FDA meeting to discuss May 2023 RANDOMIZATION 5 years + ~ Study design Pathologic major res
Slide 25: TAVO-EP Phase 2 neoadjuvant melanoma trial (draft design)
TAVO™-EP Phase 2 neoadjuvant melanoma trial (draft design) Key eligibility criteria: | Resectable stage Ill (B-D), accessible for electroporation =? = p bro a Stratification factors: _ | Stage INB vs. IC vs, MID as Treatment: TaVO™-EP D1 & D8 Q3W for 2 or 3 cycles| |& 2 Pembrolizumab 200 mg lV Q3W B
Slide 26: Melanoma: Advanced
Melanoma: Advanced KEYNOTE-695 Phase 2 in PD-1 refractory melanoma overview Survival Follow: Cohort 1a: post-anti-PD-1 treatment (MedPulser device) + Completed enrolled N=105 (target N=100}; LPI Dec 2020 Cohort 1b: post-anti-PD-1 treatment (Next Gen Devi * Closed for strategic reasons in July 2022;
Slide 27: KEYNOTE-695 Phase 2: Cohort 1a BICR summary
KEYNOTE-695 Phase 2: Cohort 1a BICR summary * The primary endpoint of KEYNOTE-695, overall response rate (ORR) by blinded independent central review (BICR), was not met. BICR ORR? of 10.2% (95% Cl 5.00, 17.97%), including 4 CR and 6 PR, did not achieve the predefined clinically meaningful response r
Slide 28: TAVO-EP 2023 milestones
TAVO™-EP 2023 milestones * Discussions with Regulatory Agencies regarding melanoma neoadjuvant [May 2023] * TAVO™-EP Phase 2 RCT in neoadjuvant melanoma initiation [4Q2023] * TAVO™-EP Phase 2 IST in neoadjuvant melanoma data update at upcoming medical meeting [4Q2023] * Discussions with Regulatory A
Slide 29: Global intratumoral cancer therapy market growth
Global intratumoral cancer therapy market growth . Several independent studies show that the intratumoral cancer therapy market grows rapidly monoclonal antibodies, vaccines, checkpoint Inhibitors, cell therapies, immune system modulators, adoptive cell transfer, cytokines, and others (left panel)*
Slide 30: OncoSec beyond TAVO-EP: Visceral Lesion Applicator (VLA)
OncoSec beyond TAVO™-EP: Visceral Lesion Applicator (VLA) VLA Organ Plasmid Gene (preclinical prototype) Entry Injection Delivery * Applicable to solid tumors located deep inside the body through our unique intra-tumoral delivery, with potential for improved anti-tumor efficacy due to abscopal effec
Slide 31: Investment opportunity
Investment opportunity Differentiated Best-in-class Robust Development Intra-tumoral Platform Therapeutic Potential Strategy TAVO™ designed to Experienced overcome key immuno- Neoadjuvant Melanoma management team and therapy shortcomings, with encouraging key strategic partnerships with improved saf
Slide 32: Experienced industry leaders with track record of success
Experienced industry leaders with track record of success Leadership Team Board of Directors Robert H. Arch, Ph.D President and Chief Executive Officer Bridget O'Keeffe, Ph.D Vice President, Clinical Development David Canton, Ph.D Vice President, Research © ® George Chi Chief Financial Officer Rober
Slide 33: Thank You
(S)oncosec IMMUNOTHERAPIES. THANK YOU!